Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin
NCT ID: NCT01720940
Last Updated: 2012-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
220 participants
INTERVENTIONAL
2012-10-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will recruit 220 subjects from 2 hospitals over a period of 3 years.
Participants are invited if they have an infection that requires prolonged vancomycin therapy (\> more than 10 days).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
continuous vancomycin infusion
continuous vancomycin infusion
24-hour continuous infusion of vancomycin
intermittent vancomycin infusion
vancomycin in this arm will be administered as intermittent infusion
intermittent vancomycin infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
continuous vancomycin infusion
24-hour continuous infusion of vancomycin
intermittent vancomycin infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented infection requiring prolonged (\> 10 days) of vancomycin therapy
* Creatinine clearance \> 50 ml/min (using Cockroft-Gault equation)
Exclusion Criteria
* Pregnancy
* Severe burns \> 40% body surface area
* Spinal cord injuries
* Participation in another interventional trial in previous 30 days
* Inability to obtain informed consent
21 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tan Tock Seng Hospital
OTHER
National University Hospital, Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medicine
Division of Infectious Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National University Hospital
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shire Yang Tan
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NUHID-001
Identifier Type: -
Identifier Source: org_study_id